Demetrios A Arvanitis Selected Research

Calcium-Binding Proteins

1/2018	The Histidine-Rich Calcium Binding Protein in Regulation of Cardiac Rhythmicity.
9/2017	Impaired calcium homeostasis is associated with sudden cardiac death and arrhythmias in a genetic equivalent mouse model of the human HRC-Ser96Ala variant.
1/2017	Phosphorylation of serine96 of histidine-rich calcium-binding protein by the Fam20C kinase functions to prevent cardiac arrhythmia.
10/2013	Abnormal calcium cycling and cardiac arrhythmias associated with the human Ser96Ala genetic variant of histidine-rich calcium-binding protein.
10/2011	Catecholaminergic-induced arrhythmias in failing cardiomyocytes associated with human HRCS96A variant overexpression.
10/2008	The Ser96Ala variant in histidine-rich calcium-binding protein is associated with life-threatening ventricular arrhythmias in idiopathic dilated cardiomyopathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Demetrios A Arvanitis Research Topics

Disease

4	Cardiac Arrhythmias (Arrythmia) 06/2021 - 10/2013
4	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 09/2017 - 10/2008
3	Cardiomyopathies (Cardiomyopathy) 07/2015 - 04/2005
2	Muscular Diseases (Myopathy) 07/2015 - 11/2009
2	Sudden Death 10/2013 - 10/2011
2	Heart Failure 01/2013 - 04/2011
2	Hypertrophy 04/2011 - 01/2011
2	Carcinoma (Carcinomatosis) 10/2008 - 11/2004
2	Neoplasms (Cancer) 10/2008 - 11/2004
1	Alzheimer Disease (Alzheimer's Disease) 01/2019
1	Cardiac Sudden Death (Sudden Cardiac Arrest) 09/2017
1	Myocardial Infarction 10/2013
1	Ventricular Tachycardia 10/2013
1	Heart Diseases (Heart Disease) 01/2010
1	Drug-Related Side Effects and Adverse Reactions 01/2010
1	Hypoxia (Hypoxemia) 01/2009
1	Squamous Intraepithelial Lesions 10/2008
1	Prostatic Neoplasms (Prostate Cancer) 11/2004
1	Hyperplasia 11/2004
1	Lung Neoplasms (Lung Cancer) 04/2003
1	Endometriosis 03/2003
1	Endometrial Neoplasms (Endometrial Cancer) 07/2002
1	Embryo Loss 02/2002

Drug/Important Bio-Agent (IBA)

6	Calcium-Binding ProteinsIBA 01/2018 - 10/2008
6	Histidine (L-Histidine)FDA Link 01/2018 - 10/2008
4	CalciumIBA 06/2021 - 10/2008
3	Proteins (Proteins, Gene)FDA Link 06/2021 - 04/2005
3	phospholambanIBA 06/2021 - 04/2011
3	Adenosine Triphosphatases (ATPase)IBA 01/2013 - 01/2011
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 09/2017
2	cysteine and glycine-rich protein 3IBA 07/2015 - 07/2014
2	Pharmaceutical PreparationsIBA 01/2010 - 04/2005
2	Messenger RNA (mRNA)IBA 10/2008 - 11/2004
2	Protein Isoforms (Isoforms)IBA 10/2008 - 11/2004
2	DNA (Deoxyribonucleic Acid)IBA 04/2003 - 07/2002
1	trans-sodium crocetinate (crocetin)IBA 01/2019
1	crocinIBA 01/2019
1	Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA 01/2018
1	KN 93IBA 01/2018
1	Phosphotransferases (Kinase)IBA 01/2017
1	Isoproterenol (Isoprenaline)FDA LinkGeneric 10/2013
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2013
1	Transcription Factors (Transcription Factor)IBA 04/2011
1	CholesterolIBA 01/2010
1	Actins (F Actin)IBA 11/2009
1	ThapsigarginIBA 01/2009
1	Carrier Proteins (Binding Protein)IBA 10/2008
1	RNA IsoformsIBA 11/2004
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 11/2004
1	Indicators and Reagents (Reagents)IBA 04/2003
1	Aromatase (CYP19)IBA 03/2003
1	Cytochrome P-450 CYP1A1 (CYP1A1)IBA 03/2003
1	Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA 02/2002
1	HomocysteineIBA 02/2002
1	Folic Acid (Vitamin M)FDA LinkGeneric 02/2002

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 01/2010
1	Radiotherapy 07/2002